Open-Label Study of the CDK4/6 Inhibitor SPH4336 in Subjects With Locally Advanced or Metastatic Liposarcomas

NCT05580588 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
14
Enrollment
INDUSTRY
Sponsor class

Stopped Although no safety issues with SPH4336 were identified, efficacy in liposarcoma patient was less than anticipated.

Conditions

Interventions

Sponsor

Shanghai Pharma Biotherapeutics USA Inc.